Redx Immunology NRES application
Research type
Research Study
Full title
The Use of Primary Cells for Immunology Drug Discovery
IRAS ID
193421
Contact name
Peter Bunyard
Contact email
Sponsor organisation
Redx Pharma
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Redx Immunology Ltd, a subsidiary of Redx Pharma Ltd, is a pharmaceutical company based in Cheshire, England, developing new drug candidates for various autoimmune diseases and drugs targeting immuno-oncology.
Redx Immunology Ltd aims to discover novel compounds to develop into targeted treatments in these therapeutic areas. Compounds will be screened in various biochemical, enzymatic and cell based assays. Critically, the patient response to currently available treatments for autoimmune disease is often dependent on patient disease phenotype, specific biomarkers of disease and disease status. As a result, although some cell based assays will be developed using characterised mammalian cell lines, for some targets these cells do not represent the functional characteristics of the compound’s target cells. Cell based assays developed by Redx Immunology Ltd will aim to model the mode of action of the target compound as closely as possible in order to develop a robust understanding of the efficacy of the proposed target. Redx Immunology Ltd is therefore proposing to isolate primary cells from anonymised human blood or tissue. Samples will be taken from healthy volunteers or patient populations and used for functional assays and toxicity screening of proposed drug candidates.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
15/NW/0889
Date of REC Opinion
10 Nov 2015
REC opinion
Favourable Opinion